Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

We recently showed that the outcome of multiple myeloma (MM) patients treated in the REPEAT study (evaluation of lenalidomide combined with low-dose cyclophosphamide and prednisone (REP) in lenalidomide-refractory MM) was markedly better than what has been described with cyclophosphamide-prednisone...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Franssen, Laurens E., Nijhof, Inger S., Bjorklund, Chad C., Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M.J., Broijl, Annemiek, Klein, Saskia K., Koene, Harry R., Bloem, Andries C., Beeker, Aart, Faber, Laura M., van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M., Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, van de Donk, Niels W.C.J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2018
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6188055/
https://ncbi.nlm.nih.gov/pubmed/30338042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26131
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge